Company / SG&A Expense
TREACE MEDICAL CONCEPTS, INC. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$47.0M
FY2025
5-year range
$4.5M / $47.0M
FY2021-FY2025
Trend
+42.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 4 consecutive years, from $4M in FY2021 to $47M in FY2025.
Based on SEC 10-K filings.
$47M in FY2025 with a 3-year CAGR of +93.0%.
Increased from $18M to $47M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +93.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- TREACE MEDICAL CONCEPTS, INC.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +93.0%, indicating consistent growth.
- In FY2025, sg&a expense increased 42.5% year-over-year.
- Lowest sg&a expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.0M | +42.5% |
| FY2024 | $33.0M | +79.0% |
| FY2023 | $18.4M | +181.9% |
| FY2022 | $6.5M | +46.5% |
| FY2021 | $4.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026